NSF Annual Review and Impact Report 2025 Now Live

Over the last year, NSF maintained a clear focus on disciplined execution — strengthening foundational capabilities, building confidence in its ability to deliver at scale, and staying firmly committed to its mission to protect and advance human health. The year also marked the successful completion of Mission 2025, a three‑year initiative designed to establish a more global and integrated operating model.
Through the dedication of teams across the organization, NSF achieved meaningful scale, delivered sustained high single‑digit growth, improved margins, and strengthened collaboration across regions and functions.
With this strong foundation in place, NSF is now entering its next strategic phase: Blueprint 2030. This forward‑looking plan builds on recent momentum and outlines how NSF will continue to accelerate its role as a global leader in public health — building systems that endure, operating with rigor and delivering on its mission to protect and advance human health worldwide.
Share this Article
How NSF Can Help You

What’s New with NSF

iNADO Partners with NSF to Support Members and Athletes
May 27, 2026iNADO is pleased to welcome NSF’s expertise and experience in support of its members and the athletes they serve
NSF Ends UK’s Three-Year Testing Gap with REG 31 Testing Designation
May 20, 2026NSF’s Oakdale laboratory becomes the UK’s sole facility offering comprehensive BS 6920 and REG 31 testing, closing a critical drinking water safety gap.
Tangent® Materials Announces Industry First: Tangent PolySheet™ CB Earns Certification to NSF 537, Becoming the First PFAS-Free NSF Standard 51 Food Equipment Material
May 20, 2026New food-grade synthetic cutting-board sheet, engineered from the ground up without per- and polyfluoroalkyl substances (PFAS), establishes a new materialsafety benchmark for food-contact and food-equipment applications.
Visit NSF at Making Pharma 2026
April 10, 2026Connect with our experts to discover how we help leading pharmaceutical and biotechnology companies achieve regulatory compliance and operational excellence.